Brightspring Health Services, Inc. · NASDAQ:BTSG
Brightspring Health Services — Q1 2026 Earnings Presentation
14 slides from Brightspring Health Services's earnings presentation, May 1, 2026
Slide 1: First Quarter 2026 Earnings Presentation
No Image No Image First Quarter 2026 Earnings Presentation May 1, 2026 1
Slide 2: Forward-Looking Statements; Non-GAAP Financial Information
No Image Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements • factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill; • No Image a pandemic, epidemic, or outbreak of a
Slide 3: A leading pharmacy and health care provider in the U.S.
No Image A leading pharmacy and health care provider in the U.S., serving large and growing markets that have significant unmet needs, with high-quality and integrated services that improve outcomes and reduce cost 3
Slide 4: BrightSpring At A Glance
No Image BrightSpring At A Glance Providing Needed Solutions Serving large and growing healthcare populations, characterized by high-cost, high-acuity, and significant complexity, with patient-centered and high-quality services delivered in preferred and lower-cost home and community settings Focu
Slide 5: BrightSpring Financial Highlights
No Image BrightSpring Financial Highlights First Quarter 2026 (from Continuing Operations) $3,614M 25.6% $190M 44.8% Revenue Revenue Growth Adj. EBITDA Adj. EBITDA Growth First Quarter 2026 ($ in millions) Y/Y Growth Pharmacy Solutions Revenue $3,171 +25.2% Infusion and Specialty Revenue 2,644 +35.5
Slide 6: Q1 2026 Revenue and Adjusted EBITDA Results
No Image Q1 2026 Revenue and Adjusted EBITDA Results (from Continuing Operations) ($ in millions) Revenue Total Revenue $3,614 +25.6% $442 $2,878 +27.9% $346 Provider Services Pharmacy Solutions $3,171 $2,532 +25.2% Q1 2025 Q1 2026 ($ in millions) Adjusted EBITDA(1) Adj. EBITDA 4.6% 5.3% margin(1) $
Slide 7: Q1 2026 Pharmacy Solutions Segment Performance
No Image Q1 2026 Pharmacy Solutions Segment Performance (from Continuing Operations) ($ in millions) Q1 2026 Revenue Infusion and Specialty Pharmacy Home and Community Pharmacy Pharmacy Solutions $3,171 +25.2% $2,532 $527 (9.2%) $581 Business Metrics +35.5% $2,644 $1,952 Prescriptions dispensed 10,7
Slide 8: Q1 2026 Provider Services Segment Performance
No Image Q1 2026 Provider Services Segment Performance (from Continuing Operations) ($ in millions) Q1 2026 Revenue Home Health Care Rehab Care Personal Care Provider Services +27.9% $442 $346 +4.3% $102 Business Metrics $98 $75 $70 +7.2% +48.9% $266 Home Health Care average 46,066 $178 +52.3% y/y d
Slide 9: Financial Performance: Three Months Ended March 31, 2026
No Image Financial Performance: Three Months Ended March 31, 2026 (from Continuing Operations) Three Months Ended March 31, 2025 vs. Three Months Ended March 31, 2026 Pharmacy Solutions Provider Services Three Months Three Months Three Months Three Months ($ in millions, Change ($ in millions, Chang
Slide 10: 2026 Guidance, Excluding Community Living
No Image 2026 Guidance, Excluding Community Living 2026 Fiscal Year Guidance Prior FY 2026 Guidance1 Updated FY 2026 Guidance1 ($ in millions) Provided February 27, 2026 Provided May 1, 2026 $12,600 – $13,100 $12,850 – $13,300 Pharmacy Revenue 10.1% – 14.5% y/y1 12.3% – 16.2% y/y1 $1,850 – $1,900 $1
Slide 11: De-leveraging Update and Capital Allocation Priorities
No Image De-leveraging Update and Capital Allocation Priorities De-leveraging driven by operational performance and capital allocation • Capex investments: 1% of revenue Long-Term Pre IPO / Post-Equity and Debt Transactions Current Leverage Cash Flow • Sustainable net working capital position Levera
Slide 12: Appendix
Appendix 12
Slide 13: Continuing Operations Non-GAAP Reconciliations
No Image Continuing Operations Non-GAAP Reconciliations For the Three Months Ended ($ in thousands) March 31, 2025 March 31, 2026 Net Income from Continuing Operations $ 9,216 $ 74,283 Income Tax (Benefit) Expense (240) 8,551 Interest Expense, net 41,763 38,615 Depreciation and Amortization 40,832 3
Slide 14: Basic and Diluted Weighted-Average Shares Outstanding Calculation
No Image Basic and Diluted Weighted-Average Shares Outstanding Calculation utilized in calculating Diluted EPS to Adjusted EPS For the Three Months Ended (in thousands) Mar 31, 2025 Jun 30, 2025 Sept 30, 2025 Dec 31, 2025 Mar 31, 2026 Publicly owned shares (excluding KKR and Walgreens) 70,721 98,627
BrightSpring Health Services — Q1 2026 Earnings Presentation on 6ix